Announcements
- Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
- Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
- Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
- Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
- Adlai Nortye Ltd. Announces Closing of Initial Public Offering
- Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
More ▼
Key statistics
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 12.30m |
Free float | 0.00 |
P/E (TTM) | -- |
Market cap | 470.48m USD |
EPS (TTM) | -7.26 USD |
--
More ▼